**Core tip:** With the increase in the *Helicobacter pylori* (*H. pylori*) resistance rate, eradication is becoming increasingly challenging. This is the first meta-analysis comprehensively focused on fourth-generation quinolones for the treatment of *H. pylori* infection. Additionally, we found that fourth-generation quinolones had a higher eradication rate (81.8%) and a lower rate of incidence of side effects (19.5%). These findings will provide a specific basis for the clinical use of fourth-generation quinolones for *H. pylori* eradication.

INTRODUCTION
============

*Helicobacter pylori* (*H. pylori*) infection plays a crucial role in the pathogenesis of gastrointestinal diseases, such as gastritis, non-ulcer dyspepsia, peptic ulcer diseases, and gastric cancer\[[@B1]\]. *H. pylori* infection affects approximately 50% of the population worldwide\[[@B2]\]. Its prevalence is approximately 70% in developing nations and approximately 20%-30% in developed nations\[[@B3]\]. Eradication of *H. pylori* facilitates peptic ulcer healing, reduces ulcer relapse rates, and prevents gastric cancer\[[@B4]\]. In the past, the recommended treatment for eradicating *H. pylori* was 7 d of standard triple therapy (STT) consisting of a proton pump inhibitor (PPI) with clarithromycin (CAM) and amoxicillin (AMPC)\[[@B5]\]. However, with the wide use of the STT regimen, the eradication rate of *H. pylori* has declined to unacceptable levels over the last decade (\< 80%) due to high resistance to metronidazole and clarithromycin\[[@B6]\]. A recent study on *H. pylori* resistance to antimicrobial agents reported that clarithromycin resistance has rapidly increased in many countries over the past decade, with resistance rates of approximately 18% in Europe, 30% in Japan, 40% in Turkey, and 50% in China; limited data are available for the United States\[[@B7]-[@B10]\]. The prevalence of *H. pylori* resistance to metronidazole is 33% in Europe and 40% in the United States, with a high resistance rate (50%-80%) in developing countries\[[@B10]\]. To overcome these difficulties, there is a need to evaluate novel regimens and antibiotics to identify effective alternative treatment strategies. Levofloxacin-based therapy is recommended by the Maastricht IV\[[@B11]\] and Maastricht V Consensus Reports\[[@B12]\]. Nonetheless, according to studies, the resistance rate to levofloxacin is approximately 22.1% in Italy and 36.9% in China; a recent study surprisingly reported a resistance rate of 31.9% in the United States\[[@B13]-[@B15]\]. Jeong et al\[[@B16]\] reported that the eradication rate was 57.1% when levofloxacin was used. Fourth-generation quinolones, including moxifloxacin, sitafloxacin, gemifloxacin, and gatifloxacin, which have broad-spectrum antibacterial activity, are active against a variety of gram-negative and gram-positive bacteria\[[@B17]\]. Recent studies have shown that fourth-generation quinolones can increase drug penetration into bacterial cells, improve the strength of activity and have better bioavailability. This group of drugs inhibits the metabolism of bacterial cells by inhibiting DNA replication and therefore enhances antibacterial activity\[[@B18]\]. Furthermore, treatment with fourth-generation quinolones has achieved a high *H. pylori* eradication rate and has been recommended in some studies\[[@B19]-[@B22]\]. Nevertheless, Chung et al\[[@B23]\] reported that the eradication rate was not satisfactory when using fourth-generation quinolones.

To evaluate the efficacy and safety of therapies containing fourth-generation quinolones, we conducted a systematic review and meta-analysis of the available data. The primary outcome measures we assessed were eradication rates, side effects, and compliance of the therapies containing fourth-generation quinolones compared with those of therapies containing non-fourth-generation quinolones. Our outcomes will provide useful evidence for clinical practice\[[@B24]\].

MATERIALS AND METHODS
=====================

Literature sources
------------------

We searched the PubMed (to February 2018), EMBASE (to February 2018), and Cochrane Central Register of Controlled Trials (Issue 2, 2018) databases. The following search terms were used for all databases: (*"Helicobacter pylori" OR H. pylori*) AND (Moxifloxacin OR Sitafloxacin OR Gemifloxacin OR Gatifloxacin); the search terms varied slightly among these databases. This meta-analysis was conducted according to the Preferred Reporting Item for Systematic Reviews and Meta-Analyses (PRISMA)\[[@B25]\].

Inclusion criteria
------------------

Articles eligible for inclusion in the meta-analysis met the following criteria: (1) randomized controlled trial (RCT) conducted; (2) methods used for the diagnosis of *H. pylori*, including the urea breath test (UBT), the rapid urease test (RUT), bacterial culture, histology, and/or fecal antigen test; (3) eradication rate made available; (4) eradication testing with UBT and/or histology performed at least 4 wk after the completion of therapy; and (5) eradication regimens in the experimental arm included fourth-generation quinolones.

Exclusion criteria
------------------

Studies were excluded under the following circumstances: (1) eradication data could not be confirmed; (2) articles and abstracts were written in a language other than English; (3) fourth-generation quinolones were included in two treatment arms; and (4) the experimental group and the control group included more than one variable (for example, the comparison of triple therapy and quadruple therapy; antibiotics and duration were different in both groups).

Data extraction
---------------

Three authors (An Y, Wang Y, and Wu S) independently extracted data from the selected studies. Any disagreements were resolved by consensus.

The extracted data included the following: the study design; number of enrolled patients in each treatment arm; diagnostic methods for confirming *H. pylori* infection before enrolling and re-checking strategies after completing the eradication study; publication time; name of the authors; location of the trial; drug regimens; duration of treatment; eradication rates by intention-to-treat (ITT) analysis and per-protocol (PP) analysis; number of successful and failed eradications; and percentage of adverse effects.

To avoid duplication of data, if a trial was repeatedly published by the same authors or institutions, only the most recently published or most informative study was included.

Risk of bias
------------

The quality of RCTs with available full text was assessed using the risk of bias assessment tool developed by the Cochrane Handbook for Systematic Reviews of Interventions\[[@B26]\]. Two independent reviewers assessed the risk of bias through six domain-based evaluations, including selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective outcome reporting), and other bias. Each indicator was scored by low risk of bias, unclear risk of bias, and high risk of bias. Any disagreement was discussed and decided by a third reviewer. We also employed a funnel plot and Egger's test to assess the presence of publication bias.

Statistical analysis
--------------------

The statistical analysis was performed using the meta-analysis software STATA12.0 (StataCorp LP, College Station, TX, United States). The primary outcomes of the meta-analysis were the *H. pylori* eradication rate and therapy-related side effects among the trials comparing the control and experimental groups based on ITT analysis. For each trial, we calculated the odds ratio (OR) for the primary measure. The ORs were presented with 95% confidence intervals (CIs); in addition, a *P*-value \< 0.05 was considered significant. The degree of heterogeneity among the trial results was estimated using the χ*^2^* statistic (*P-*value \< 0.10 considered significant) and the *I*^2^ test (0%-25%, 25%-50%, 50%-75%, and \> 75% represented insignificant, low, moderate, and high heterogeneity, respectively). If significant heterogeneity (*P* \< 0.10 or *I*^2^ \> 50%) was achieved, we employed the random effects model to combine the effect sizes of the included studies. When no significant heterogeneity was found, we used fixed effects to pool the data. Additionally, subgroup analyses were performed based on the location and different types of fourth-generation quinolones.

RESULTS
=======

Description of the studies
--------------------------

The bibliographical search yielded a total of 548 studies from PubMed, Embase, and the Cochrane Central Register of Controlled Trials. Among these articles, we excluded 144 due to duplication and 175 that were unrelated. We selected 229 potential studies for detailed assessment, among which 68 were excluded because there was no control group. We also excluded 67 review articles, comments, or letters. Thirty-three articles were excluded because of the inclusion of fourth-generation quinolones in two regimens, 14 articles were non-RCTs, 11 articles were excluded due to an inappropriate drug regimen, and 19 articles had data that could not be determined. Then, 17 articles were selected for further evaluation. Five articles were excluded because the data repeated those in other studies, one study did not state the methods for diagnosis of *H. pylori*, and one study was published in Japanese. Ultimately, 10 studies (two abstracts and eight full-text articles) met the inclusion criteria and were included in the systematic review and meta-analysis (Figure [1](#F1){ref-type="fig"}). These 10 studies\[[@B27]-[@B36]\] are summarized in Table [1](#T1){ref-type="table"} based on our meta-analysis. The quality assessment is reported in Table [2](#T2){ref-type="table"}.

###### 

Characteristics of studies included in the meta-analysis

  **Year-Author**           **Location**                  ***H. pylori* infection initial diagnosis/re-checking**   **Control group** **-Day**   **Fourth-generation quinolone group-Day**   **Eradication rate (ITT)** **(control group/fourth- generation quinolone group)**   **Eradication rate (PP)** **(control group/fourth- generation quinolone group)**   **Compliance**   **Side effects**
  ------------------------- ----------------------------- --------------------------------------------------------- ---------------------------- ------------------------------------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------- ------------------
  2017-Mansour Ghanaei, F   Iran                          14C-UBT or histology                                      BPAC-10                      BPAG-10                                     89% (81/91)/77% (70/91)                                                             91% (81/90)/77.8% (70/90)                                                                           
  2015-Masoodi, M           Iran                          13C-UBT, RUT pathology test                               OBAC-10                      OBAG-10                                     61.6% (37/60)/66.6% (40/60)                                                         67.2% (37/55)/72.7% (40/55)                                                        97.1%/98.3%      37/19
  2014-Rakici, H            Turkey                        pistology, stool antigen test                             LanAL-10                     LanAM-10                                    89.4% (92/103)/87.8% (93/106)                                                       92% (92/100)/91.8% (93/102)                                                        96%/95.1%        \-
  2013-Murakami, K          Japan                         culture method, RUT, UBT                                  LanAL-7                      LanAS-7                                     43.1% (28/65)/70% (49/70)                                                           43.7% (28/84)/72.1% (49/68)                                                        98.4%/94.1%      11/11
  2012-Zeng, Z              China                         14C-UBT                                                   EAC-7                        EAM-7                                       78.9% (180/228)/79.4% (181/228)                                                     82.9% (180/217)/84.2% (181/215)                                                    \-               \-
  2009-Lu, NH               China                         14C-UBT                                                   EAC-7                        EAM-7                                       90.3% (28/31)/85.7% (24/28)                                                         \-                                                                                 \-               \-
  2008-Kilic, ZM            Turkey                        gastroscopy, histology, RUT, 13C-UBT                      RBCAC-14 EAC-14              RBCAM-14                                    76.7% (23/30)/66.7% (20/30)                                                         76.7% (23/30)/66.7% (20/30)                                                        100%/100%        11/13
  EAM-14                    63.3% (19/30)/53.3% (16/30)   63.3% (19/30)/53.3% (16/30)                               100%/100%                    17/21                                                                                                                                                                                                                               
  2007-Bago, P              Croatia                       RUT, histology, culture test, 13C-UBT                     LanMetC-7 LanAC-7            LanMetM-7                                   70.4% (50/71)/93.5% (58/62)                                                         75.8% (50/66)/96.7% (58/60)                                                        \-               
  LanAM-7                   78.2% (61/78)/86.4% (57/66)   80.2% (61/76)/90.5% 57/63)                                                                                                                                                                                                                                                                                                 
  2005-Kist, M              Germany                       13C-UBT                                                   EAC-7 ETC-7                  EAM-7                                       72.5% (58/80)/87.5% (70/80)                                                         78% (58/74)/89% (70/79)                                                            \-               \-
  ETM-7                     75% (60/80)/90% (72/80)       79% (60/76)/92% (72/78)                                                                                                                                                                                                                                                                                                    
  2005-Nista, EC            Italy                         Histological examination, 13C-UBT                         ETC-7 EAC-7                  ETM-7                                       75% (60/80)/90% (72/80)                                                             78.9% (60/76)/92.3% (72/78)                                                        \-               29/11
  EAM-7                     72.5% (58/80)/87.5% (70/80)   78.4% (58/74)/88.6% (70/79)                               26/10                                                                                                                                                                                                                                                            

A: Amoxicillin; B: Bismuth; C: Clarithromycin; E: Esomeprazole G: Gemifloxacin; Lan: Lansoprazole; L: Levofloxacin; M: Moxifloxacin; Met: Metronidazole; O: Omeprazole; P: Pantoprazole; S: Sitafloxacin; RBC: Ranitidine bismuth citrate; -: Not reported.

![Flow diagram of the identified and selected trials.](WJG-24-3302-g001){#F1}

###### 

Risk assessment of included studies

  **Year-Author**           **Random sequence generation (selection bias)**   **Allocation concealment (selection bias)**   **Blinding of participants and personnel (performance bias)**   **Blinding of outcome assessment (detection bias)**   **Incomplete outcome data (attrition bias)**   **Selective reporting (reporting bias)**   **Other bias**
  ------------------------- ------------------------------------------------- --------------------------------------------- --------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------- ------------------------------------------ ----------------
  2017-Mansour Ghanaei, F   L                                                 H                                             H                                                               L                                                     L                                              L                                          L
  2015-Masoodi, M           L                                                 L                                             L                                                               H                                                     L                                              L                                          L
  2014-Rakici, H            L                                                 H                                             H                                                               H                                                     L                                              U                                          L
  2013-Murakami, K          L                                                 H                                             L                                                               H                                                     L                                              L                                          L
  2012-Zeng, Z              U                                                 U                                             U                                                               U                                                     L                                              U                                          U
  2009-Lu, NH               U                                                 U                                             U                                                               U                                                     L                                              U                                          U
  2008-Kilic, ZM            L                                                 H                                             H                                                               H                                                     L                                              L                                          U
  2007-Bago, P              L                                                 L                                             L                                                               H                                                     L                                              L                                          L
  2005-Kist, M              H                                                 H                                             H                                                               H                                                     L                                              H                                          L
  2005- Nista, EC           L                                                 H                                             H                                                               H                                                     L                                              L                                          L

L: Low risk of bias; H: High risk of bias; U: Unclear risk of bias.

Efficacy of H. pylori eradication
---------------------------------

There were 10 studies with a total of 2198 patients in our meta-analysis; of these patients, 1107 received therapy without fourth-generation quinolone and 1091 received therapy with fourth-generation quinolone. The pooled eradication rates were 75.4% (835/1107) in the control group and 81.8% (892/1091) in the experimental group by ITT analysis. The pooled OR was 0.661 (95%CI: 0.447-0.977; *P* = 0.038) using the random effects model (*I*^2^ = 66.2%, *P* = 0.000; Figure [2](#F2){ref-type="fig"}).

![Forest plot of eradication rate of the therapies containing non-fourth-generation quinolones *vs* that of the therapies containing fourth-generation quinolones (intention-to-treat analysis).](WJG-24-3302-g002){#F2}

Moreover, the pooled eradication rates were 79.1% (835/1055) in the control group and 84.7% (892/1053) in the experimental group by PP analysis. The pooled OR was 0.663 (95%CI: 0.433-1.016; *P* = 0.059) using the random effects model (*I*^2^ = 64.4%, *P* = 0.000).

The results of ITT showed that the eradication rates of therapies containing non-fourth-generation quinolones was significantly lower than those of therapies containing fourth-generation quinolones.

Subgroup analyses
-----------------

Additional subgroup analyses for the meta-analysis were performed due to heterogeneity. We analyzed different types of fourth-generation quinolones, covering seven moxifloxacin trials and three other trials (including 1 sitafloxacin and 2 gemifloxacin). In the moxifloxacin subgroup, the pooled eradication rates were 77.3% (689/891) in the control group and 84.3% (733/870) in the experimental group (OR = 0.614, 95%CI: 0.403-0.935; *P* = 0.023; Figure [3](#F3){ref-type="fig"}) by ITT analysis, and the rates were 81.3% (689/847) in the control group and 87.3% (689/891) in the experimental group by PP analysis (OR = 0.614, 95%CI: 0.395-0.956; *P* = 0.031). In the other subgroup, the pooled eradication rates were 67.6% (146/216) in the control group and 71.9% (159/221) in the experimental group (OR = 0.846, 95%CI: 0.274-2.614; *P* = 0.772; Figure [3](#F3){ref-type="fig"}) by ITT analysis, and the rates were 70.2% (146/208) in the control group and 74.6% (159/213) in the experimental group by PP analysis (OR = 0.860, 95%CI: 0.239-3.091; *P* = 0.817). This subgroup analysis showed that the regimen with moxifloxacin achieved a higher eradication rate than the regimen without moxifloxacin. However, there was no significant difference in the eradication rate in the other subgroup.

![Forest plot of the sub-analysis according to types of fourth-generation quinolone (intention-to-treat analysis).](WJG-24-3302-g003){#F3}

We also conducted subgroup analysis by region (seven trials in Asia and three trials in Europe). In the Asian subgroup, the pooled eradication rates of the control group and the experimental group were 76.5% (488/638) and 76.7% (493/643), respectively, by ITT analysis (OR = 1.051; 95%CI: 0.671-1.646; *P* = 0.827; Figure [4](#F4){ref-type="fig"}) and 79.6% (488/613) and 80.0% (493/616), respectively, by PP analysis (OR = 1.072; 95%CI: 0.627-1.833; *P* = 0.800). In the European subgroup, the pooled eradication rates of the control group and the experimental group were 74.0% (347/469) and 89.1% (399/448), respectively, by ITT analysis (OR = 0.661; 95%CI: 0.447-0.977; *P* = 0.000; Figure [4](#F4){ref-type="fig"}) and 78.5% (347/442) *vs* 91.3% (399/437), respectively, by PP analysis (OR = 0.361; 95% CI: 0.240-0.544; *P* = 0.000). The results showed that therapies containing fourth-generation quinolones may not be advisable treatments for *H. pylori* infection in Asia. However, the use of fourth-generation quinolones in Europe can significantly improve the eradication rate.

![Forest plot of the sub-analysis according to region (intention-to-treat analysis).](WJG-24-3302-g004){#F4}

Side effects
------------

Of the 10 studies, four studies provided data regarding side effects. The results showed that common symptoms included nausea, diarrhea, black stool, and taste disturbance. The occurrence of total side effects in the control group was significantly higher than that in the experimental group by ITT analysis (30.6% *vs* 19.5%, OR = 1.874; 95%CI: 1.120-3.137; *P* = 0.017; Figure [5](#F5){ref-type="fig"}).

![Forest plot of the side effects of the therapies containing fourth-generation quinolones *vs* the therapies containing non-fourth-generation quinolones.](WJG-24-3302-g005){#F5}

Compliance
----------

Four studies included in the meta-analysis provided information about compliance. The results showed high compliance (\> 95%), and there were no significant differences between the study groups.

Risk of bias in publication
---------------------------

Egger's regression test suggested that there was no significant bias (*P* = 0.725) in the ITT analysis, while the funnel plot showed a slightly asymmetrical distribution (Figure [6](#F6){ref-type="fig"}).

![Funnel plot of the therapies containing non-fourth-generation quinolones *vs* the therapies containing fourth-generation quinolones (intention-to-treat analysis).](WJG-24-3302-g006){#F6}

DISCUSSION
==========

*H. pylori* infection is marked by a vast prevalence and strong association with various gastric diseases\[[@B37]\]. Therapeutic regimens range from STT to the present novel regimens, such as quadruple therapy with bismuth, sequential treatment, concomitant therapy, and hybrid therapy\[[@B38],[@B39]\]. However, the treatment effects are still not ideal due to bacterial antibiotic resistance\[[@B40]\]. Thus, it is necessary to evaluate novel regimens or antibiotics\[[@B41]\]. With the resistance rate to the third-generation quinolone levofloxacin continuing to increase, resulting in a low eradication rate\[[@B16]\], therapies containing fourth-generation quinolones might be suitable for the treatment of *H. pylori* infection.

This meta-analysis indicated that therapies containing fourth-generation quinolones had a higher clearance rate than other therapies by ITT and PP analyses. The mechanism of action of fourth-generation quinolones against *H. pylori* is to inhibit bacterial DNA gyrase, thus interfering with bacterial DNA replication\[[@B42]\]. These fourth-generation quinolones embed in the broken DNA chain and form complexes to inhibit nicking and closing activity, achieving a bactericidal effect\[[@B43]\]. However, according to Graham, who had given a report card to grade *H. pylori* therapy by ITT, the eradication rate is still poor (grade D, 81%-84%)\[[@B44]\]. This may be related to the low compliance of patients\[[@B27],[@B33]\]. The choice of fourth-generation quinolones, the duration of treatment, and the difference in PPI also influenced the pooled eradication rates of therapies containing fourth-generation quinolones.

The subgroup analyses of antibiotic species conducted in this study demonstrated that regimens containing moxifloxacin were superior to those not containing moxifloxacin (84.3% *vs* 71.9%). This finding might be consistent with a previous systematic review\[[@B45]\], but the eradication rate was still less than 85% by ITT analysis. The main reason was that the resistance rate of *H. pylori* to moxifloxacin was higher, even reaching up to 27.0% when analyzed by the E-test\[[@B31]\]. This phenomenon reminds us that it is best to conduct a susceptibility test to choose antibiotics reasonably.

We also conducted subgroup analysis by region. The eradication rate of fourth-generation quinolone treatments in Europe was much higher than that in Asia (89.1% *vs* 76.7%). This difference may be due to the low utilization rate of antibiotics in Europe\[[@B8]\]. In Asia, the abuse of antibiotics is very common, which leads to a high drug resistance rate of *H. pylori*. According to a multiregion prospective 7-year study by Liu et al\[[@B46]\], the prevalence of *H. pylori* after moxifloxacin treatment was 17.2%. Resistance to moxifloxacin was reported to be similar to that of levofloxacin, ranging from 14.9% to 20.0% in Turkey\[[@B29]\]. The increasing antibiotic resistance rate makes the eradication of *H. pylori* more difficult.

The rate of incidence of adverse events in the control groups was higher than that in the experimental groups. The pooled OR (1.874) indicated that the use of fourth-generation quinolones in the treatment of *H. pylori* infection can reduce the incidence of adverse reactions. This result indicates that therapies containing fourth-generation quinolones are safer.

The main limitation of this meta-analysis is potential biases. On the one hand, the largest number of studies was conducted using moxifloxacin; only one study used sitafloxacin, and two used gemifloxacin. This selection had a certain effect on the pooled eradication rate and may also be a particularly important issue in the use of a single antibiotic to eradicate *H. pylori* for clinical treatment. On the other hand, all included studies were performed in Europe and Asia, with no studies conducted in Africa or America. Because *H. pylori* infection occurs worldwide, our results may not be appropriate for global generalization. These two factors lead to the bias of conclusion. In addition, most of the studies in our meta-analysis had problems with concealment of allocation and blinding, which caused the selection bias. The restrictions on the language of publication also imply other bias, and thus our meta-analysis may not reflect all the outcomes.

Our analysis also implied other limitations. Most articles reporting a control arm were conducted using clarithromycin; our analysis is therefore especially lacking detailed data on levofloxacin. Two of the 10 included studies were abstracts, generating concerns regarding the data extraction and quality assessment of these studies and affecting the reliability of our results.

In conclusion, this meta-analysis indicates that therapies containing fourth-generation quinolones can achieve a higher eradication rate of *H. pylori* infection, but the eradication rate remains poor. In the absence of other drug options or in cases of patient allergy to penicillin, such regimens might be considered as a rescue treatment based on antimicrobial susceptibility testing. Further investigation is necessary to draw more solid conclusions about the use of fourth-generation quinolones in the treatment of *H. pylori* infection. In addition, we will study more effective therapies for *H. pylori* infection if necessary.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The resistance of *Helicobacter pylori* (*H. pylori*) to antibiotics is increasing and often leads to the failure of eradication treatment. Recent studies have reported that therapies containing fourth-generation quinolones remain effective against antibiotic-resistant *H. pylori*. However, the efficacy and safety of these therapies require further study. This is the first meta-analysis comparing the curative effect of fourth-generation quinolones with that of other therapies in regard to eradicating *H. pylori*.

Research motivation
-------------------

In the Maastricht IV and Maastricht V Consensus Reports, levofloxacin-based therapy is recommended when the first treatment fails. Therapies containing fourth-generation quinolones are not mentioned. Our meta-analysis focused on eradication rates, side effects and compliance of therapies containing fourth-generation quinolones when compared with therapies using non-fourth-generation quinolones.

Research objectives
-------------------

This meta-analysis aimed to clarify the effect of fourth-generation quinolones on the eradication of *H. pylori* infection and provide some evidence for clinical practice.

Research methods
----------------

The meta-analysis was conducted according to the PRISMA criteria. We searched the PubMed, EMBASE, and Cochrane Library databases. The outcome was to calculate the pooled eradication rate and therapy-related side effects among the trials, comparing the control and experimental groups. We calculated the odds ratio of each trial for the primary measure. The odds ratios were presented with 95% confidence intervals, and a *P*-value \< 0.05 was considered significant. This methodology was also performed for subgroup analysis.

Research results
----------------

Available data from 10 studies showed that treatment with a fourth-generation quinolone could achieve a higher *H. pylori* eradication rate and decrease the side effects, but the eradication rate is less than acceptable. Fourth-generation quinolones can significantly improve the eradication rate in Europe but not in Asia.

Research conclusions
--------------------

Quinolone resistance increases with age and duration of use. It is essential for practitioners to use quinolone antibiotics in the clinic reasonably. This study comprehensively analyzed the role of fourth-generation quinolone in the treatment of *H. pylori* infection. Our results suggested that fourth-generation quinolones are not ideal for eradication of *H. pylori*. Treatment based on antibiotic susceptibility testing might be more valid and obtain a higher rate of eradication of *H. pylori* infection, particularly in areas where resistance to antibiotics develops rapidly.

Research perspectives
---------------------

According to reports that mutations at positions 87 and 91 of gyrA are the main cause of *H. pylori* resistance to fourth-generation quinolones, we will continue to pay attention to the resistance rate to fourth-generation quinolones globally. We will also focus on rapid genotyping methods, such as detecting gyrA mutations in *H. pylori*. Further studies of sitafloxacin, gemifloxacin, and gatifloxacin are imperative to draw more solid conclusions about the use of fourth-generation quinolones for the eradication of *H. pylori* infection.
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